- Conditions
- Cardiopulmonary Bypass, Altered Heparin Response
- Interventions
- Heparin, ATryn
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–23
of 23
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Disease, Chronic, Pediatric Kidney Disease, Renal Insufficiency, Chronic, Blood Coagulation Disorders in Children
- Interventions
- phlebotomy
- Diagnostic Test
- Lead sponsor
- Children's Healthcare of Atlanta
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiac Surgery, Cardiopulmonary Bypass
- Interventions
- AT-III (Human), Placebo
- Biological · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 41
- States / cities
- Orange, California • San Francisco, California • Stanford, California + 36 more
- Conditions
- Sickle Cell Disease, Hemolytic Anemia
- Interventions
- Clinical Evaluations, Laboratory Studies
- Procedure · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Thrombophilia Due to Acquired Antithrombin III Deficiency
- Interventions
- Recombinant antithrombin (rhAT)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Preeclampsia
- Interventions
- Recombinant human antithrombin (ATryn), Normal Saline 0.9%
- Biological · Other
- Lead sponsor
- rEVO Biologics
- Industry
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
- Conditions
- Hemophilia
- Interventions
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 8
- States / cities
- Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more
- Conditions
- Hemophilia A
- Interventions
- Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Multiple Sclerosis, Relapse
- Interventions
- Blood samples and processing
- Diagnostic Test
- Lead sponsor
- Regina Elena Cancer Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Deep Venous Thrombosis
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 18 more
- Conditions
- Extracorporeal Membrane Oxygenation Complication, Cardiopulmonary Bypass
- Interventions
- Antithrombin III
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Antithrombin III Deficiency, Covid19
- Interventions
- Antithrombin III
- Drug
- Lead sponsor
- Enrique Ginzburg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Trauma Injury, Thromboembolism, Venous Thromboembolism
- Interventions
- Thrombate infusion, Placebo
- Drug
- Lead sponsor
- Bryan Cotton
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Miami, Florida • Nashville, Tennessee + 1 more
- Conditions
- Hemophilia
- Interventions
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 11 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Las Vegas, Nevada + 2 more
- Conditions
- Congenital Antithrombin Deficiency
- Interventions
- Atenativ
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Peoria, Illinois + 2 more
- Conditions
- Postoperative Hemorrhage
- Interventions
- Antithrombin (Recombinant), Placebo
- Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 4 Days to 30 Days
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- ATIII Deficiency
- Interventions
- Anti-thrombin III, Placebo
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 7 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Antithrombin III Deficiency
- Interventions
- Recombinant human antithrombin (rhAT)
- Biological
- Lead sponsor
- rEVO Biologics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • St Louis, Missouri • New York, New York
- Conditions
- Neonates on ECMO
- Interventions
- Recombinant Antithrombin
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Minute to 30 Days
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Antithrombin Deficiency, Congenital
- Interventions
- Recombinant Human Antithrombin (rhAT)
- Biological
- Lead sponsor
- rEVO Biologics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 2
- States / cities
- Marietta, Georgia • Charleston, South Carolina
- Conditions
- Portal Vein Thrombosis, Cirrhosis, Liver
- Interventions
- Antithrombin III, Placebo
- Drug · Other
- Lead sponsor
- Jonathan Stine
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Acquired Antithrombin Deficiency
- Interventions
- Human plasma derived antithrombin, Placebo
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more
- Conditions
- Congenital Heart Disease
- Interventions
- Antithrombin III, Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 1 Day to 180 Days
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, New York